JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Closed

SectorHealthcare

16.76 0.96

Overview

Share price change

24h

Current

Min

16.4

Max

16.95

Key metrics

By Trading Economics

Sales

132M

160M

Employees

627

EBITDA

126M

4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+79.11% upside

Market Stats

By TradingEconomics

Market Cap

882M

1.9B

Previous open

15.8

Previous close

16.76

News Sentiment

By Acuity

37%

63%

127 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

Arcus Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Oct 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 Oct 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 Oct 2025, 21:20 UTC

Earnings

Correction to IBM 3Q Sales Jump Article

22 Oct 2025, 20:57 UTC

Earnings

SAP Posts Higher 3Q Revenue, Operating Profit

22 Oct 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 Oct 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 Oct 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 Oct 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 Oct 2025, 23:15 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 Oct 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 Oct 2025, 22:02 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 Oct 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 Oct 2025, 21:58 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 Oct 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 Oct 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 Oct 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 Oct 2025, 21:47 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 Oct 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 Oct 2025, 21:46 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 Oct 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 Oct 2025, 21:28 UTC

Market Talk
Earnings

Correction to Alcoa Tariff Market Talk

22 Oct 2025, 21:25 UTC

Earnings

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 Oct 2025, 21:17 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 Oct 2025, 21:09 UTC

Market Talk
Earnings

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 Oct 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 Oct 2025, 20:59 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 Oct 2025, 20:51 UTC

Earnings

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 Oct 2025, 20:44 UTC

Earnings

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Comparison

Price change

Arcus Biosciences Inc Forecast

Price Target

By TipRanks

79.11% upside

12 Months Forecast

Average 32.33 USD  79.11%

High 54 USD

Low 14 USD

Based on 12 Wall Street analysts offering 12 month price targets forArcus Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.01 / 8.75Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Neutral Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

127 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat